Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study: a registry-based descriptive study
Uložené v:
| Názov: | Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study: a registry-based descriptive study |
|---|---|
| Autori: | David Lang, Wolfgang Haslinger, Kaveh Akbari, Mario Scala, Benedikt Hergan, Christian Asel, Andreas Horner, Romana Wass, Elmar Brehm, Bernhard Kaiser, Bernd Lamprecht |
| Prispievatelia: | Universitätsbibliothek |
| Zdroj: | Lung Cancer (Auckl) Lung Cancer: Targets and Therapy, Vol Volume 11, Pp 113-121 (2020) |
| Informácie o vydavateľovi: | Informa UK Limited, 2020. |
| Rok vydania: | 2020 |
| Predmety: | nivolumab, carcinoembryonic antigen, Targets and Therapy [Lung Cancer], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, 03 medical and health sciences, platinum doublet chemotherapy, 0302 clinical medicine, RECIST, cyfra 21-1, CYFRA 21-1, pembrolizumab, recist, RC254-282, Original Research |
| Popis: | To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy.Patients having received platinum-based chemo-(CHT) and PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) combination therapy were retrospectively followed. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cytokeratin-19 fragments (CYFRA 21-1) and neuron specific enolase (NSE) were routinely measured at NSCLC diagnosis. The marker with the highest relative elevation was defined "leading STM", its change was assessed between CHT-ICI as well as mono-ICI maintenance initiation and the respective subsequent restaging. Corresponding computed tomography evaluations were analyzed using response evaluation criteria in solid tumors (RECIST). For CHT-ICI combination and subsequent mono-ICI-maintenance therapy, leading STM and RECIST response were evaluated regarding progression-free (PFS) and overall survival (OS) in Kaplan-Meier analyses.Among 80 CHT-ICI patients (41% women, mean age 63 years), median PFS was 5 months (M;4,9), median OS was 15M (10,/). PFS was significantly (p=0.042) longer, when the leading STM had decreased at first restaging under CHT-ICI combination therapy (9M (5,12; n=41) vs 5M (3,6; n=16)). In the 54 (67.5%) patients who received subsequent mono-ICI maintenance therapy, STM decrease was similarly associated with significantly (p |
| Druh dokumentu: | Article Conference object Other literature type |
| Popis súboru: | text/html |
| Jazyk: | English |
| ISSN: | 1179-2728 |
| DOI: | 10.2147/lctt.s286228 |
| Prístupová URL adresa: | https://www.dovepress.com/getfile.php?fileID=64983 https://pubmed.ncbi.nlm.nih.gov/33376433 https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e https://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-article-LCTT https://www.scilit.net/article/7cddf6848bac8c8841477b14229327cb?action=show-references https://europepmc.org/article/MED/33376433 https://www.dovepress.com/serum-tumor-marker-dynamics-as-predictive-biomarkers-in-nsclc-chemo-im-peer-reviewed-fulltext-article-LCTT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755331 https://epub.jku.at/obvulioa/content/titleinfo/5697358 https://pubmed.ncbi.nlm.nih.gov/33376433/ https://permalink.obvsg.at/ULI/AC16119783 https://doi.org/10.2147/lctt.s286228 https://epub.jku.at/id/5697358 |
| Rights: | CC BY NC |
| Prístupové číslo: | edsair.doi.dedup.....a32b9d8905623458600a3562b746e40f |
| Databáza: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | To evaluate serum tumor markers (STM) as predictive biomarkers in advanced non-small cell lung cancer (NSCLC) treated with chemo-immunotherapy.Patients having received platinum-based chemo-(CHT) and PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) combination therapy were retrospectively followed. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cytokeratin-19 fragments (CYFRA 21-1) and neuron specific enolase (NSE) were routinely measured at NSCLC diagnosis. The marker with the highest relative elevation was defined "leading STM", its change was assessed between CHT-ICI as well as mono-ICI maintenance initiation and the respective subsequent restaging. Corresponding computed tomography evaluations were analyzed using response evaluation criteria in solid tumors (RECIST). For CHT-ICI combination and subsequent mono-ICI-maintenance therapy, leading STM and RECIST response were evaluated regarding progression-free (PFS) and overall survival (OS) in Kaplan-Meier analyses.Among 80 CHT-ICI patients (41% women, mean age 63 years), median PFS was 5 months (M;4,9), median OS was 15M (10,/). PFS was significantly (p=0.042) longer, when the leading STM had decreased at first restaging under CHT-ICI combination therapy (9M (5,12; n=41) vs 5M (3,6; n=16)). In the 54 (67.5%) patients who received subsequent mono-ICI maintenance therapy, STM decrease was similarly associated with significantly (p |
|---|---|
| ISSN: | 11792728 |
| DOI: | 10.2147/lctt.s286228 |